prednisone has been researched along with Duncan Disease in 105 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recently, the use of targeted synthetic or biological disease-modifying anti-rheumatic drugs (ts/bDMARDs) in addition to conventional synthetic (cs)DMARDs including methotrexate (MTX) for rheumatoid arthritis (RA) has increased." | 8.02 | Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. ( Akashi, K; Asaoku, H; Ayano, M; Fujisaki, T; Harada, T; Iwasaki, H; Kato, K; Kohno, K; Mitoma, H; Miyamoto, T; Miyamura, T; Miyoshi, H; Mori, Y; Muta, T; Niiro, H; Ohshima, K; Oryoji, K; Oshiro, Y; Sakamoto, A; Sawabe, T; Takase, K; Takeshita, M; Urata, S; Yamamoto, H; Yoshimoto, G, 2021) |
| "Other iatrogenic immunodeficiency-associated lymphoproliferative disorders induced by immunosuppressive drugs, such as methotrexate (MTX-LPD), exhibit numerous pathological findings." | 7.96 | Methotrexate-associated lymphoproliferative disorder demonstrating composite lymphoma of EBV-negative diffuse large B-cell lymphoma and EBV-positive mucocutaneous ulcer. ( Carreras, J; Kikuti, YY; Kondo, Y; Moriya, K; Nakamura, N; Shiraiwa, S, 2020) |
| "We report an extremely rare case of massive methotrexate-associated lymphoproliferative disorder (MTX-LPD) arising in the retromolar triangle and lung of a patient with rheumatoid arthritis." | 7.80 | Methotrexate-associated lymphoproliferative disorder arising in the retromolar triangle and lung of a patient with rheumatoid arthritis. ( Harada, H; Ishii, Y; Kudoh, M; Matsumoto, K; Omura, K; Sato, Y, 2014) |
| "Recently, the use of targeted synthetic or biological disease-modifying anti-rheumatic drugs (ts/bDMARDs) in addition to conventional synthetic (cs)DMARDs including methotrexate (MTX) for rheumatoid arthritis (RA) has increased." | 4.02 | Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. ( Akashi, K; Asaoku, H; Ayano, M; Fujisaki, T; Harada, T; Iwasaki, H; Kato, K; Kohno, K; Mitoma, H; Miyamoto, T; Miyamura, T; Miyoshi, H; Mori, Y; Muta, T; Niiro, H; Ohshima, K; Oryoji, K; Oshiro, Y; Sakamoto, A; Sawabe, T; Takase, K; Takeshita, M; Urata, S; Yamamoto, H; Yoshimoto, G, 2021) |
| "Other iatrogenic immunodeficiency-associated lymphoproliferative disorders induced by immunosuppressive drugs, such as methotrexate (MTX-LPD), exhibit numerous pathological findings." | 3.96 | Methotrexate-associated lymphoproliferative disorder demonstrating composite lymphoma of EBV-negative diffuse large B-cell lymphoma and EBV-positive mucocutaneous ulcer. ( Carreras, J; Kikuti, YY; Kondo, Y; Moriya, K; Nakamura, N; Shiraiwa, S, 2020) |
| "We report an extremely rare case of massive methotrexate-associated lymphoproliferative disorder (MTX-LPD) arising in the retromolar triangle and lung of a patient with rheumatoid arthritis." | 3.80 | Methotrexate-associated lymphoproliferative disorder arising in the retromolar triangle and lung of a patient with rheumatoid arthritis. ( Harada, H; Ishii, Y; Kudoh, M; Matsumoto, K; Omura, K; Sato, Y, 2014) |
| "Immunodeficiency-related lymphoproliferative disorders (IR-LPD) may occur in the setting of immunosuppressive therapy with methotrexate and TNF-α antagonists." | 3.77 | Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sézary syndrome. ( Curry, JL; Diwan, AH; Duvic, M; Jones, DM; Prieto, VG; Vega, F, 2011) |
| "We studied rejection, allograft function and side effects, such as hypertension, renal dysfunction and hypercholesterolemia, in seven patients switched from cyclosporine-based triple-drug immunosuppression to FK 506." | 3.69 | Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK 506. ( Armitage, JM; Fricker, FJ; Swenson, JM, 1995) |
| "Unfortunately, pulmonary thromboembolism occurred 2 weeks later, and the patient's condition was not alleviated through active treatment." | 1.51 | Application of contrast-enhanced ultrasonography in the diagnosis of post-kidney transplant lymphoproliferative disorder in native kidney- a case report. ( Lan, HX; Lei, YY; Lu, MD; Ma, L; Wang, W; Xie, XY; Zhang, JC; Zhao, HJ, 2019) |
| "While both are rare, lupus erythematosus panniculitis of the orbit is even more exceptional; this patient's indolent, chronic relapsing course distinguished itself from the typical aggression of orbital T-cell lymphoma." | 1.48 | Orbital T-cell lymphoma versus lupus panniculitits: a T-cell-mediated spectrum of orbital lymphoproliferative disease. ( Huggins, AB; Kim, C; Rabinowitz, MP, 2018) |
| "Post-transplant hypercalcemia is a major problem in renal transplant recipients, which may negatively affect both graft and patient survival." | 1.48 | Extreme hypercalcemia in a kidney transplant recipient. ( Demir, E; Karaoglan, C; Sair, B; Sever, MS; Turkmen, A; Yazici, H; Yegen, G, 2018) |
| "Prednisone use was associated with higher mortality [HR = 3." | 1.46 | Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy. ( Boice, J; Colombel, JF; Cornillie, F; D'Haens, G; Ghosh, S; Hommes, DW; Huang, Z; Huyck, S; Lindgren, S; Panes, J; Prantera, C; Reinisch, W, 2017) |
| "However, her facial palsy did not resolve, and she died 6 months after diagnosis with pneumonia and sepsis." | 1.38 | Multifocal cranial plasmablastic lymphoma as a rare manifestation of posttransplant lymphoproliferative disorder. ( Bastani, B; Ghods, AJ; Jabbari, M; Jenabi, A; Mooraki, A; Shayanfar, N; Ziari, MB, 2012) |
| "The differential diagnosis of spinal cord compression in a patient who has had a transplant should include primary presentation of PTLD." | 1.35 | Extradural thoracic spinal cord compression: unusual initial presentation of post-transplant lymphoproliferative disorder. ( Bakker, NA; Coppes, MH; Slart, RH; van Dijk, JM; van Imhoff, GW; Verschuuren, EA, 2008) |
| " EBV-related polymorphic PTLD was diagnosed and treated with discontinuation of cyclosporine, reduction in prednisone dosage and administration of EBV-specific cytotoxic T lymphocytes." | 1.34 | Conjunctival posttransplantation lymphoproliferative disorder. ( Irshad, FA; Onciu, MM; Walton, RC; Wilson, TD, 2007) |
| "We propose that autism may be part of the autoimmune disease spectrum of ALPS in this child, and this case represents a novel manifestation and target organ involvement in this disease." | 1.31 | Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome. ( Arnold, S; Chatila, T; Shenoy, S, 2000) |
| "Median survival was 40 months." | 1.31 | Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia. ( Go, RS; Li, CY; Lust, JA; Phyliky, RL; Tefferi, A, 2000) |
| "Precursor B cell lymphoblastic lymphoma has not been previously reported as a form of posttransplant lymphoproliferative disease." | 1.31 | Epstein-Barr virus-negative precursor B cell lymphoblastic lymphoma after liver transplantation: a unique form of posttransplant lymphoproliferative disease. ( Borges, E; Ferry, JA; Friedmann, AM, 2002) |
| "Four epidemiologic types of Kaposi sarcoma (KS) are known: classic KS, endemic African KS, epidemic or acquired immunodeficiency syndrome-related KS, and KS associated with immunosuppressive therapy." | 1.29 | The appearance of Kaposi sarcoma during corticosteroid therapy. ( David, M; Hodak, E; Sandbank, M; Trattner, A, 1993) |
| "Of 10 patients with non-Hodgkin's lymphoma 2 achieved complete remission and 5 a partial response." | 1.27 | Treatment of refractory lymphoproliferative diseases with daily, low-dose vincristine, continuous infusion of bleomycin, and high-dose prednisone. ( Gomez, GA; Han, T; Henderson, ES; Ozer, H, 1984) |
| "Seven patients with autoimmune hemolytic anemia (AIHA) associated with an underlying lymphoproliferative disorder were treated with intravenous immunoglobulin." | 1.27 | Rapid transient reversal of anemia and long-term effects of maintenance intravenous immunoglobulin for autoimmune hemolytic anemia in patients with lymphoproliferative disorders. ( Besa, EC, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (8.57) | 18.7374 |
| 1990's | 16 (15.24) | 18.2507 |
| 2000's | 39 (37.14) | 29.6817 |
| 2010's | 32 (30.48) | 24.3611 |
| 2020's | 9 (8.57) | 2.80 |
| Authors | Studies |
|---|---|
| Hong, J | 1 |
| Johnson, WT | 1 |
| Kartan, S | 1 |
| Gonsalves, AS | 1 |
| Fenkel, JM | 1 |
| Gong, JZ | 1 |
| Porcu, P | 1 |
| Afify, Z | 3 |
| Orjuela-Grimm, M | 3 |
| Smith, CM | 3 |
| Dalal, M | 3 |
| Ford, JB | 3 |
| Pillai, P | 3 |
| Robles, JM | 3 |
| Reddy, S | 3 |
| McCormack, S | 3 |
| Ehrhardt, MJ | 3 |
| Ureda, T | 3 |
| Alperstein, W | 3 |
| Edington, H | 3 |
| Miller, TP | 3 |
| Rubinstein, JD | 4 |
| Kavanaugh, M | 3 |
| Bukowinski, AJ | 3 |
| Friehling, E | 3 |
| Rivers, JM | 3 |
| Chisholm, KM | 3 |
| Marks, LJ | 3 |
| Mason, CC | 3 |
| Zhang, JC | 1 |
| Lan, HX | 1 |
| Zhao, HJ | 1 |
| Lei, YY | 1 |
| Ma, L | 1 |
| Xie, XY | 1 |
| Lu, MD | 1 |
| Wang, W | 1 |
| Moriya, K | 1 |
| Kikuti, YY | 1 |
| Carreras, J | 1 |
| Kondo, Y | 1 |
| Shiraiwa, S | 1 |
| Nakamura, N | 1 |
| Yasunaga, M | 1 |
| Yasuda, Y | 1 |
| Honda, A | 1 |
| Maki, H | 1 |
| Toyama, K | 1 |
| Masamoto, Y | 1 |
| Bujo, C | 1 |
| Amiya, E | 1 |
| Hatano, M | 1 |
| Ono, M | 1 |
| Komuro, I | 1 |
| Kurokawa, M | 1 |
| Mouchel, PL | 1 |
| Syrykh, C | 1 |
| Laurent, C | 1 |
| Tavitian, S | 1 |
| Gauthier, M | 1 |
| Burns, DM | 1 |
| Clesham, K | 1 |
| Hodgson, YA | 1 |
| Fredrick, L | 1 |
| Haughton, J | 1 |
| Lannon, M | 1 |
| Hussein, H | 1 |
| Shin, JS | 1 |
| Hollows, RJ | 1 |
| Robinson, L | 1 |
| Byrne, C | 1 |
| McNamara, C | 1 |
| Vydianath, B | 1 |
| Lennard, AL | 1 |
| Fields, P | 1 |
| Johnson, R | 1 |
| Wright, J | 1 |
| Fox, CP | 1 |
| Cwynarski, K | 1 |
| Chaganti, S | 1 |
| Sprangers, B | 1 |
| Riella, LV | 1 |
| Dierickx, D | 2 |
| Harada, T | 1 |
| Iwasaki, H | 1 |
| Muta, T | 1 |
| Urata, S | 1 |
| Sakamoto, A | 1 |
| Kohno, K | 2 |
| Takase, K | 1 |
| Miyamura, T | 1 |
| Sawabe, T | 1 |
| Asaoku, H | 1 |
| Oryoji, K | 1 |
| Fujisaki, T | 1 |
| Mori, Y | 1 |
| Yoshimoto, G | 1 |
| Ayano, M | 1 |
| Mitoma, H | 1 |
| Miyamoto, T | 1 |
| Niiro, H | 1 |
| Yamamoto, H | 1 |
| Oshiro, Y | 1 |
| Miyoshi, H | 1 |
| Ohshima, K | 1 |
| Takeshita, M | 1 |
| Akashi, K | 1 |
| Kato, K | 1 |
| Shah, R | 1 |
| Breese, EH | 1 |
| Burns, KC | 1 |
| Mangino, JL | 1 |
| Norris, RE | 1 |
| Lee, L | 1 |
| Mizukawa, B | 1 |
| O'Brien, MM | 1 |
| Phillips, CL | 1 |
| Perentesis, JP | 1 |
| Pommert, L | 1 |
| Absalon, MJ | 1 |
| DeStefano, CB | 1 |
| Malkovska, V | 1 |
| Rafei, H | 1 |
| Shenoy, A | 1 |
| Fitzpatrick, K | 1 |
| Aggarwal, A | 1 |
| Catlett, JP | 1 |
| Uchida, T | 1 |
| Inoue, M | 1 |
| Hua, J | 1 |
| Tajima, S | 1 |
| Ota, Y | 1 |
| Hagihara, M | 1 |
| Huggins, AB | 1 |
| Kim, C | 1 |
| Rabinowitz, MP | 1 |
| Demir, E | 1 |
| Karaoglan, C | 1 |
| Yegen, G | 1 |
| Sair, B | 1 |
| Yazici, H | 1 |
| Turkmen, A | 1 |
| Sever, MS | 1 |
| García-Cadenas, I | 1 |
| Yáñez, L | 1 |
| Jarque, I | 1 |
| Martino, R | 1 |
| Pérez-Simón, JA | 1 |
| Valcárcel, D | 1 |
| Sanz, J | 1 |
| Bermúdez, A | 1 |
| Muñoz, C | 1 |
| Calderón-Cabrera, C | 1 |
| García, E | 1 |
| Alonso, L | 1 |
| Suárez-Lledó, M | 1 |
| González Vicent, M | 1 |
| Heras, I | 1 |
| Viguria, MC | 1 |
| Batlle, M | 1 |
| Vázquez, L | 1 |
| López, J | 1 |
| Solano, C | 1 |
| Yamaguchi, J | 1 |
| Fujino, T | 1 |
| Isa, R | 1 |
| Nishiyama, D | 1 |
| Kuwahara-Ota, S | 1 |
| Kawaji, Y | 1 |
| Tsukamoto, T | 1 |
| Chinen, Y | 1 |
| Shimura, Y | 1 |
| Kobayashi, T | 1 |
| Horiike, S | 1 |
| Nakamura, S | 1 |
| Kuroda, J | 1 |
| Toyonaga, H | 1 |
| Fukushima, M | 1 |
| Shimeno, N | 1 |
| Inokuma, T | 1 |
| Stardelova, KG | 1 |
| Stojanovik, A | 1 |
| Jovanovska, RP | 1 |
| Stavrik, S | 1 |
| Dimitrova, M | 1 |
| Kostova, NM | 1 |
| Serafimoski, V | 1 |
| Podoltsev, N | 1 |
| Zhang, B | 1 |
| Yao, X | 1 |
| Bustillo, I | 1 |
| Deng, Y | 1 |
| Cooper, DL | 1 |
| Zimmermann, H | 2 |
| Trappe, RU | 3 |
| Kudoh, M | 1 |
| Harada, H | 1 |
| Matsumoto, K | 1 |
| Sato, Y | 1 |
| Omura, K | 1 |
| Ishii, Y | 1 |
| Kuriyama, T | 1 |
| Kawano, N | 1 |
| Yamashita, K | 1 |
| Ueda, A | 1 |
| Masson, P | 1 |
| Henderson, L | 1 |
| Chapman, JR | 1 |
| Craig, JC | 1 |
| Webster, AC | 1 |
| Sedrak, M | 1 |
| Muthukumar, A | 1 |
| Elghetany, MT | 1 |
| Qian, YW | 1 |
| Alobaid, A | 1 |
| Torlakovic, E | 1 |
| Kongkham, P | 1 |
| Krasuska-Sławińska, E | 1 |
| Minko-Chojnowska, I | 1 |
| Pawłowska, J | 1 |
| Dembowska-Bagińska, B | 1 |
| Pronicki, M | 1 |
| Olczak-Kowalczyk, D | 1 |
| Tu, S | 1 |
| Zhong, D | 1 |
| Wu, X | 1 |
| Li, Y | 1 |
| Song, C | 1 |
| Bahmanyar, M | 1 |
| Shakibazad, N | 1 |
| Imanieh, MH | 1 |
| Dehghani, SM | 1 |
| Morschhauser, F | 1 |
| Mollee, P | 1 |
| Zaucha, JM | 1 |
| Dreyling, MH | 1 |
| Dührsen, U | 2 |
| Reinke, P | 4 |
| Verhoef, G | 1 |
| Subklewe, M | 1 |
| Hüttmann, A | 1 |
| Tousseyn, T | 1 |
| Salles, G | 2 |
| Kliem, V | 2 |
| Hauser, IA | 2 |
| Tarella, C | 1 |
| Van Den Neste, E | 1 |
| Gheysens, O | 1 |
| Anagnostopoulos, I | 4 |
| Leblond, V | 3 |
| Riess, H | 4 |
| Choquet, S | 3 |
| D'Haens, G | 1 |
| Reinisch, W | 1 |
| Colombel, JF | 1 |
| Panes, J | 1 |
| Ghosh, S | 1 |
| Prantera, C | 1 |
| Lindgren, S | 1 |
| Hommes, DW | 1 |
| Huang, Z | 1 |
| Boice, J | 1 |
| Huyck, S | 1 |
| Cornillie, F | 1 |
| Henry, DD | 1 |
| Hunger, SP | 1 |
| Braylan, RC | 1 |
| Dharnidharka, VR | 1 |
| Bakker, NA | 1 |
| van Dijk, JM | 1 |
| Slart, RH | 1 |
| Coppes, MH | 1 |
| van Imhoff, GW | 1 |
| Verschuuren, EA | 1 |
| Johnston, A | 1 |
| Espinouse, D | 1 |
| Felman, P | 1 |
| André, P | 1 |
| Berger, F | 1 |
| Coiffier, B | 1 |
| Dubal, DB | 1 |
| Mueller, S | 1 |
| Ruben, BS | 1 |
| Engstrom, JW | 1 |
| Josephson, SA | 1 |
| Trappe, R | 3 |
| Hinrichs, C | 1 |
| Appel, U | 1 |
| Babel, N | 2 |
| Neumayer, HH | 1 |
| Budde, K | 1 |
| Dreyling, M | 2 |
| Schüttrumpf, S | 1 |
| Mergenthaler, HG | 2 |
| Schlattmann, P | 1 |
| Doerken, B | 1 |
| Canessa, PA | 1 |
| Pratticò, L | 1 |
| Fiasella, F | 1 |
| Cavazza, A | 1 |
| Bacigalupo, B | 1 |
| Fedeli, F | 1 |
| Curry, JL | 1 |
| Prieto, VG | 1 |
| Jones, DM | 1 |
| Vega, F | 1 |
| Duvic, M | 1 |
| Diwan, AH | 1 |
| Ninan, MJ | 1 |
| Datta, YH | 1 |
| Pinho-Apezzato, ML | 1 |
| Tannuri, U | 1 |
| Tannuri, AC | 1 |
| Mello, ES | 1 |
| Lima, F | 1 |
| Gibelli, NE | 1 |
| Santos, MM | 1 |
| Ayoub, AA | 1 |
| Maksoud-Filho, JG | 1 |
| Velhote, MC | 1 |
| Silva, MM | 1 |
| Andrade, WC | 1 |
| Miyatani, HT | 1 |
| Jakobiec, FA | 1 |
| Stacy, RC | 1 |
| Mehta, M | 1 |
| Fay, A | 1 |
| Adams, B | 1 |
| Lazarchick, J | 1 |
| Medina, AM | 1 |
| Willner, IR | 1 |
| Neville, B | 1 |
| Murphy, E | 1 |
| Stuart, R | 1 |
| Costa, LJ | 1 |
| Cooles, FA | 1 |
| Jackson, GH | 1 |
| Menon, G | 1 |
| Isaacs, JD | 1 |
| Rezania, K | 1 |
| Soliven, B | 1 |
| Baron, J | 1 |
| Lin, H | 1 |
| Penumalli, V | 1 |
| van Besien, K | 1 |
| Miyagi, S | 1 |
| Sekiguchi, S | 1 |
| Kawagishi, N | 1 |
| Akamatsu, Y | 1 |
| Satoh, K | 1 |
| Takeda, I | 1 |
| Fukushima, D | 1 |
| Kobayashi, Y | 1 |
| Tokodai, K | 1 |
| Fujimori, K | 1 |
| Satomi, S | 1 |
| Gross, TG | 6 |
| Orjuela, MA | 1 |
| Perkins, SL | 1 |
| Park, JR | 2 |
| Lynch, JC | 2 |
| Cairo, MS | 2 |
| Smith, LM | 1 |
| Hayashi, RJ | 1 |
| Jenabi, A | 1 |
| Mooraki, A | 1 |
| Jabbari, M | 1 |
| Shayanfar, N | 1 |
| Ghods, AJ | 1 |
| Ziari, MB | 1 |
| Bastani, B | 1 |
| Na, HK | 1 |
| Ye, BD | 1 |
| Yang, SK | 1 |
| Yang, DH | 1 |
| Jung, KW | 1 |
| Kim, KJ | 1 |
| Byeon, JS | 1 |
| Myung, SJ | 1 |
| Huh, J | 1 |
| Kim, JH | 1 |
| Risitano, AM | 1 |
| Camera, A | 1 |
| Chiurazzi, F | 1 |
| Rossi, M | 1 |
| D'Arco, AM | 1 |
| Rotoli, B | 1 |
| Nathanson, S | 1 |
| Debray, D | 1 |
| Delarue, A | 1 |
| Deschênes, G | 1 |
| Du, MQ | 1 |
| Diss, TC | 1 |
| Liu, H | 1 |
| Ye, H | 1 |
| Hamoudi, RA | 1 |
| Cabeçadas, J | 1 |
| Dong, HY | 1 |
| Harris, NL | 1 |
| Chan, JK | 1 |
| Rees, JW | 1 |
| Dogan, A | 1 |
| Isaacson, PG | 1 |
| Watts, RG | 1 |
| Hilliard, LM | 1 |
| Berkow, RL | 1 |
| Bunnapradist, S | 1 |
| Vo, A | 1 |
| Toyoda, M | 2 |
| Alsabeh, R | 1 |
| Lockhart, C | 1 |
| Puliyanda, D | 1 |
| Jordan, SC | 2 |
| Zamkoff, KW | 1 |
| Bergman, S | 1 |
| Beaty, MW | 1 |
| Buss, DH | 1 |
| Pettenati, MJ | 1 |
| Hurd, DD | 1 |
| Boye, J | 1 |
| Elter, T | 1 |
| Engert, A | 1 |
| Hayashi, K | 1 |
| Joko, H | 1 |
| Koirala, TR | 1 |
| Onoda, S | 1 |
| Jin, ZS | 1 |
| Munemasa, M | 1 |
| Ohara, N | 1 |
| Oda, W | 1 |
| Tanaka, T | 1 |
| Oka, T | 1 |
| Kondo, E | 1 |
| Yoshino, T | 1 |
| Takahashi, K | 1 |
| Yamada, M | 1 |
| Akagi, T | 1 |
| KYLE, RA | 1 |
| McPARLAND, CE | 1 |
| DAMESHEK, W | 1 |
| Orjuela, M | 1 |
| Cheung, YK | 1 |
| Alobeid, B | 1 |
| Morris, E | 1 |
| Bucuvalas, JC | 1 |
| Greiner, TC | 2 |
| Hinrich, SH | 1 |
| Kaufman, SS | 2 |
| Langnas, AN | 2 |
| McDonald, RA | 1 |
| Ryckman, FC | 1 |
| Shaw, BW | 2 |
| Sudan, DL | 1 |
| Huang, Q | 1 |
| Chang, KL | 1 |
| Gaal, KK | 1 |
| Weiss, LM | 1 |
| Elstrom, RL | 1 |
| Andreadis, C | 1 |
| Aqui, NA | 1 |
| Ahya, VN | 1 |
| Bloom, RD | 1 |
| Brozena, SC | 1 |
| Olthoff, KM | 1 |
| Schuster, SJ | 1 |
| Nasta, SD | 1 |
| Stadtmauer, EA | 1 |
| Tsai, DE | 1 |
| Snow, AL | 1 |
| Vaysberg, M | 1 |
| Krams, SM | 1 |
| Martinez, OM | 1 |
| Fohrer, C | 1 |
| Caillard, S | 1 |
| Koumarianou, A | 1 |
| Ellero, B | 1 |
| Woehl-Jaeglé, ML | 1 |
| Meyer, C | 1 |
| Epailly, E | 1 |
| Chenard, MP | 1 |
| Lioure, B | 1 |
| Natarajan-Ame, S | 1 |
| Maloisel, F | 1 |
| Lutun, P | 1 |
| Kessler, R | 1 |
| Moulin, B | 1 |
| Bergerat, JP | 1 |
| Wolf, P | 1 |
| Herbrecht, R | 1 |
| Jäger, U | 2 |
| Davi, F | 1 |
| Oertel, S | 3 |
| Williams, KM | 1 |
| Higman, MA | 1 |
| Chen, AR | 1 |
| Schwartz, CL | 1 |
| Wharam, M | 1 |
| Colombani, P | 1 |
| Arceci, RJ | 1 |
| Jacobs, P | 2 |
| Ruff, P | 1 |
| Wood, L | 1 |
| Moodley, D | 1 |
| Mansvelt, E | 1 |
| Hummel, M | 1 |
| Lehmkuhl, H | 2 |
| Jonas, S | 2 |
| Papp-Vary, M | 1 |
| Hetzer, R | 2 |
| Dörken, B | 2 |
| Walton, RC | 1 |
| Onciu, MM | 1 |
| Irshad, FA | 1 |
| Wilson, TD | 1 |
| Kebelmann-Betzing, C | 1 |
| Snavely, NR | 1 |
| Sonabend, M | 1 |
| Rosen, T | 1 |
| Starzl, TE | 2 |
| Nalesnik, MA | 1 |
| Porter, KA | 1 |
| Ho, M | 1 |
| Iwatsuki, S | 1 |
| Griffith, BP | 1 |
| Rosenthal, JT | 1 |
| Hakala, TR | 1 |
| Hardesty, RL | 1 |
| Gomez, GA | 1 |
| Han, T | 1 |
| Ozer, H | 1 |
| Henderson, ES | 1 |
| Neftel, KA | 1 |
| Stahel, R | 1 |
| Müller, OM | 1 |
| Morell, A | 1 |
| Arrenbrecht, S | 1 |
| Swenson, JM | 1 |
| Fricker, FJ | 1 |
| Armitage, JM | 1 |
| Swinnen, LJ | 1 |
| Mullen, GM | 1 |
| Carr, TJ | 1 |
| Costanzo, MR | 1 |
| Fisher, RI | 1 |
| Tzakis, AG | 1 |
| Reyes, J | 2 |
| Todo, S | 1 |
| Nour, B | 1 |
| Shapiro, R | 1 |
| Jordan, M | 1 |
| McCauley, J | 1 |
| Armitage, J | 1 |
| Fung, JJ | 2 |
| Trattner, A | 1 |
| Hodak, E | 1 |
| David, M | 1 |
| Sandbank, M | 1 |
| Keung, YK | 1 |
| Cobos, E | 1 |
| Meyerrose, GE | 1 |
| Roberson, GH | 1 |
| Newell, KA | 1 |
| Alonso, EM | 1 |
| Kelly, SM | 1 |
| Rubin, CM | 1 |
| Thistlethwaite, JR | 1 |
| Whitington, PF | 1 |
| Piusińska, A | 1 |
| Sułek, K | 1 |
| Ilnicki, S | 1 |
| Betiuk, B | 1 |
| Nast, CC | 1 |
| Moudgil, A | 1 |
| Zuo, XJ | 1 |
| McCarthy, M | 1 |
| Ramage, J | 1 |
| McNair, A | 1 |
| Gane, E | 1 |
| Portmann, B | 1 |
| Pagliuca, A | 1 |
| Rela, M | 1 |
| Heaton, N | 1 |
| Mufti, GJ | 1 |
| Williams, R | 1 |
| Hinrichs, SH | 1 |
| Winner, J | 1 |
| Sammut, PH | 1 |
| Walker, RE | 1 |
| McCrindle, BW | 1 |
| Coles, JG | 1 |
| West, LJ | 1 |
| McDiarmid, S | 1 |
| Goss, J | 1 |
| Seu, P | 1 |
| Shackleton, C | 2 |
| Vargas, J | 1 |
| Ament, M | 1 |
| Busuttil, R | 1 |
| Cacciarelli, TV | 1 |
| Green, M | 1 |
| Jaffe, R | 1 |
| Mazariegos, GV | 1 |
| Jain, A | 1 |
| Balfour, IC | 1 |
| Wall, D | 1 |
| Luisiri, A | 1 |
| Sotelo, C | 1 |
| Smets, F | 1 |
| Vajro, P | 1 |
| Cornu, G | 1 |
| Reding, R | 1 |
| Otte, JB | 1 |
| Sokal, E | 1 |
| Shenoy, S | 1 |
| Arnold, S | 1 |
| Chatila, T | 1 |
| Koffman, BH | 1 |
| Kennedy, AS | 1 |
| Heyman, M | 1 |
| Colonna, J | 1 |
| Howell, C | 1 |
| Mamzer-Bruneel, MF | 1 |
| Lomé, C | 1 |
| Morelon, E | 1 |
| Levy, V | 1 |
| Bourquelot, P | 1 |
| Jacobs, F | 1 |
| Gessain, A | 1 |
| Mac Intyre, E | 1 |
| Brousse, N | 1 |
| Kreis, H | 1 |
| Hermine, O | 1 |
| Go, RS | 1 |
| Tefferi, A | 1 |
| Li, CY | 1 |
| Lust, JA | 1 |
| Phyliky, RL | 1 |
| Solary, E | 1 |
| Mannone, L | 1 |
| Moreau, D | 1 |
| Caillot, D | 1 |
| Casasnovas, RO | 1 |
| Guy, H | 1 |
| Grandjean, M | 1 |
| Wolf, JE | 1 |
| André, F | 1 |
| Fenaux, P | 1 |
| Canal, P | 1 |
| Chauffert, B | 1 |
| Wotawa, A | 1 |
| Bayssas, M | 1 |
| Genne, P | 1 |
| Tattevin, P | 1 |
| Papo, T | 1 |
| Caumes, E | 1 |
| Merle-Béral, H | 1 |
| Piette, JC | 1 |
| Sasai, K | 1 |
| Yamabe, H | 1 |
| Dodo, Y | 1 |
| Kashii, S | 1 |
| Nagata, Y | 1 |
| Hiraoka, M | 1 |
| Martire, B | 1 |
| Burattini, MG | 1 |
| De Santis, A | 1 |
| Schettini, F | 1 |
| De Mattia, D | 1 |
| Suryanarayan, K | 1 |
| Natkunam, Y | 1 |
| Berry, G | 1 |
| Bangs, CD | 1 |
| Cherry, A | 1 |
| Dahl, G | 1 |
| Borges, E | 1 |
| Ferry, JA | 1 |
| Friedmann, AM | 1 |
| Shank, BB | 1 |
| Kelley, CD | 1 |
| Nisce, LZ | 1 |
| Nori, D | 1 |
| Melosky, B | 1 |
| Karim, M | 1 |
| Chui, A | 1 |
| McBride, M | 1 |
| Cameron, EC | 1 |
| Yeung, CK | 1 |
| Landsberg, D | 1 |
| Keown, PA | 1 |
| Preiksaitis, JK | 1 |
| Diaz-Mitoma, F | 1 |
| Mirzayans, F | 1 |
| Roberts, S | 1 |
| Tyrrell, DL | 1 |
| Besa, EC | 1 |
| King, HS | 1 |
| Ben-Izhak, C | 1 |
| Shechter, Y | 1 |
| Tatarsky, I | 1 |
| Wellens, F | 1 |
| Estenne, M | 1 |
| de Francquen, P | 1 |
| Goldstein, J | 1 |
| Leclerc, JL | 1 |
| Primo, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Patients With Posttransplant Lymphoproliferative Disorder (PTLD) With a Sequential Treatment Consisting of Anti-CD20 Antibody Rituximab and CHOP+GCSF Chemotherapy (Including 1st+2nd Amendment)[NCT01458548] | Phase 2 | 70 participants (Actual) | Interventional | 2002-12-31 | Terminated (stopped due to This study had an major amendment in 12/2006 introducing risk stratified sequential treatment (RSST). The modified protocol is registered with NCT00590447.) | ||
| Treatment of Patients With Posttransplant Lymphoproliferative Disorder (PTLD) With a Sequential Treatment Consisting of Anti-CD20 Antibody Rituximab and CHOP+GCSF Chemotherapy (PTLD-1/3)[NCT00590447] | Phase 2 | 152 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Crohn's Disease European Registry. A Prospective, Observational, Postmarketing Safety Surveillance Registry of Patients Treated With Remicade® or Standard Therapy[NCT00705614] | 2,662 participants (Actual) | Observational | 2003-07-31 | Completed | |||
| Phase II Study of Cyclophosphamide, Prednisone and Rituximab (CPR) in Children, Adolescents and Young Adults With B-lymphocyte Antigen CD20 (CD20) Positive Post-Transplant Lymphoproliferative Disease (PTLD) Following Solid Organ Transplantation (SOT)[NCT00066469] | Phase 2 | 55 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| An Open-Label, One Arm, Phase I Safety Study of Anti-CD20 Antibody (Rituximab, Rituxan) Therapy in the Treatment of Primary Sjogren's Syndrome[NCT00101829] | Phase 1 | 12 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With 4 Courses of Rituximab SC Followed by 4 Courses of Rituximab SC, 4 Courses of Rituximab SC Combined With CHOP-21 or 6 Courses of Rituximab SC Combined With Alt[NCT02042391] | Phase 2 | 60 participants (Actual) | Interventional | 2015-02-03 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of participant fatalities was evaluated throughout the study. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 30 |
| Standard Therapy | 14 |
| Switched to Remicade | 4 |
The number of participants with demyelinating neurological disorders was evaluated. Demyelinating neurological disorders were defined as multiple sclerosis, optic neuritis, peripheral syndromes such as peripheral neuropathy, mononeuropathy multipex, cranial neuropathies, Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, and transverse myelitis. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 4 |
| Standard Therapy | 1 |
| Switched to Remicade | 0 |
The number of participants wtih hematologic conditions was evaluated. A hematologic condition was defined as thrombocytopenia, neutropenia, pancytopenia, granulocytopenia, leukopenia, or aplastic anemia. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 50 |
| Standard Therapy | 11 |
| Switched to Remicade | 7 |
The number of participants with infusion-related reactions and/or hypersensitivity was evaluated. An infuson-related reaction/hypersensitivity was defined as as an acute reaction, including anaphylactic shock that occurs after the onset of the infusion or within the 1- to 2-hour observation period following the end of the infusion. Delayed hypersensitivity reactions (myalgia and/or arthralgia with fever and rash within 14 days of the infusion) were included. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 173 |
| Standard Therapy | 1 |
| Switched to Remicade | 28 |
The number of participants wtih lymphoproliferative disorders and/or malignancies was evaluated. A lymphoproliferative disorder and /or malignancy included, but was not limited to, lymphoma, gastrointestinal cancer, skin cancer (including basocellular and squamous carcinoma, melanoma) and in situ cervical carcinoma. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 49 |
| Standard Therapy | 21 |
| Switched to Remicade | 8 |
The number of participants with new or worsening congestive heart failure was evaluated throughout the study. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 1 |
| Standard Therapy | 1 |
| Switched to Remicade | 0 |
The number of participants experiencing serious infections was evaluated. Serious infections included, but were not limited to, tuberculosis, opportunistic infections (such as Pneumocystis carinii [PCP] pneumonia, listeriosis, atypical mycobacteria, and histoplasmosis), salmonellosis,and serious viral infections. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 132 |
| Standard Therapy | 47 |
| Switched to Remicade | 18 |
The duration of hospital stays for Crohn's Disease in the prior 6 months was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Days (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=657,418 ,0) | Visit 2 (n=304,126, 33) | Visit 3 (n=216, 58, 35) | Visit 4 (n=151, 60, 24) | Visit 5 (n=105, 35, 34) | Visit 6 (n=107, 49, 19) | Visit 7 (n=109, 45, 25) | Visit 8 (n=98, 29, 23) | Visit 9 (n=80, 38, 17) | Visit 10 (n=85, 29, 27) | Visit 11 (n=63, 19, 18) | |
| Remicade | 12.2 | 14.4 | 14.2 | 12.6 | 11.7 | 10.8 | 10.6 | 9.5 | 12.4 | 10.1 | 11.4 |
| Standard Therapy | 10.8 | 12.0 | 9.4 | 8.5 | 9.8 | 13.7 | 10.2 | 16.3 | 6.9 | 8.0 | 8.7 |
| Switched to Remicade | NA | 13.0 | 13.5 | 9.1 | 7.1 | 18.3 | 10.0 | 14.7 | 10.7 | 9.0 | 18.1 |
The number of participant hospital stays for Crohn's Disease in the prior 6 months was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Hospital Stays (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1539, 1121, 0) | Visit 2 (n=1418, 920, 100) | Visit 3 (n=1334, 827, 152) | Visit 4 (n=1285, 779, 168) | Visit 5 (n=1221, 714, 188) | Visit 6 (n=1170, 665, 208) | Visit 7 (n=1111, 615, 219) | Visit 8 (n=1099, 589, 233) | Visit 9 (n=1046, 562, 229) | Visit 10 (n=1031, 535, 235) | Visit 11 (n=1006, 541, 248) | |
| Remicade | 0.7 | 0.3 | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Standard Therapy | 0.5 | 0.2 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Switched to Remicade | NA | 0.5 | 0.4 | 0.2 | 0.3 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 |
The number of participants undergoing surgical procedures for Crohn's Disease in the prior 6 months was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Surgical Procedures (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Basline; n=660, 419, 0) | Visit 2 (n=304, 126, 33) | Visit 3 (n=217, 57, 36) | Visit 4 (n=153, 60, 24) | Visit 5 (n=106, 36, 34) | Visit 6 (n=108, 49, 19) | Visit 7 (n=109, 45, 25) | Visit 8 (n=98, 29, 23) | Visit 9 (n=82, 38, 17) | Visit 10 (n=85, 29, 27) | Visit 11 (n=63, 19, 18) | |
| Remicade | 171 | 135 | 121 | 68 | 50 | 49 | 48 | 43 | 38 | 38 | 34 |
| Standard Therapy | 81 | 51 | 23 | 16 | 14 | 21 | 20 | 12 | 13 | 13 | 6 |
| Switched to Remicade | NA | 7 | 12 | 8 | 14 | 11 | 6 | 7 | 8 | 8 | 8 |
The number of participants with a draining fistula was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1541, 1120, 0) | Visit 2 (n=1420, 920, 100) | Visit 3 (n=1334, 827, 152) | Visit 4 (n=1285, 779, 168) | Visit 5 (n=1221, 714, 188) | Visit 6 (n=1169, 666, 208) | Visit 7 (n=1110, 615, 219) | Visit 8 (n=1097, 588, 233) | Visit 9 (n=1046, 562, 229) | Visit 10 (n=1030, 535, 235) | Visit 11 (n=1006, 541, 248) | |
| Remicade | 349 | 211 | 170 | 146 | 125 | 114 | 97 | 105 | 98 | 85 | 87 |
| Standard Therapy | 96 | 51 | 41 | 31 | 29 | 26 | 31 | 23 | 32 | 15 | 16 |
| Switched to Remicade | NA | 16 | 19 | 12 | 15 | 15 | 15 | 16 | 15 | 20 | 20 |
The participant assessment of overall health status was evaluated at baseline and each study visit. The overall health status questionnaire asked participants to rate their current health status over the prior 24 hours as 1=best possible, 2=much better than average, 3=better than average, 4=average, 5=worse than average, 6=much worse than average, or 7=worst possible. Scores ranged from 1 to 7 with lower scores indicating better health status. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Score on a Scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1526, 1116, 0) | Visit 2 (n=1344, 903, 95) | Visit 3 (n=1280, 809, 146) | Visit 4 (n=1217, 755, 162) | Visit 5 (n=1160, 704, 184) | Visit 6 (n=1110, 649, 202) | Visit 7 (n=1046, 606, 212) | Visit 8 (n=1044, 573, 221) | Visit 9 (n=999, 544, 223) | Visit 10 (n=963, 520, 227) | Visit 11 (n=956, 527, 235) | |
| Remicade | 4.3 | 3.3 | 3.2 | 3.2 | 3.1 | 3.1 | 3.1 | 3.1 | 3.1 | 3.0 | 3.0 |
| Standard Therapy | 3.9 | 3.3 | 3.1 | 3.0 | 3.1 | 3.0 | 3.0 | 3.0 | 2.9 | 2.8 | 2.8 |
| Switched to Remicade | NA | 3.9 | 3.6 | 3.5 | 3.2 | 3.4 | 3.3 | 3.2 | 3.2 | 3.1 | 3.1 |
The Harvey-Bradshaw Index of Crohn's Disease Acitivity was evaluated at each study visit. The Harvey-Bradshaw Index evaluates participants' general health in the day prior in the domains of well being, abdominal pain, number of liquid stools per day, and abdominal mass and complications and was evaluated on the day of the study visit. The score is derived from a 0-4 score for general well being, 0-3 for abdmonial pain, raw score for number of liquid stools per day, 0-3 for abdominal mass, and raw score for complications. The total score is from 0 to infinity, with lower scores indicating better outcomes. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Score on a Scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1505, 1106, 0) | Visit 2 (n=1320, 876, 91) | Visit 3 (n=1250, 785, 143) | Visit 4 (n=1196, 742, 159) | Visit 5 (n=1127, 692, 181) | Visit 6 (n=1070, 647, 199) | Visit 7 (n=1023, 592, 209) | Visit 8 (n=1015, 562, 224) | Visit 9 (n=953, 546, 219) | Visit 10 (n=936, 526, 225) | Visit 11 (n=918, 525, 238) | |
| Remicade | 8.2 | 4.1 | 3.7 | 3.8 | 3.7 | 3.6 | 3.6 | 3.6 | 3.6 | 3.4 | 3.4 |
| Standard Therapy | 6.2 | 3.8 | 3.5 | 3.2 | 3.4 | 3.1 | 3.0 | 3.2 | 2.9 | 2.7 | 2.7 |
| Switched to Remicade | NA | 6.0 | 4.4 | 4.8 | 4.9 | 4.5 | 4.1 | 4.1 | 4.4 | 4.3 | 4.2 |
The participant work/daily activity status score was evaluated at each study visit. The work/daily activity questionnaire asked participants to rate their level of daily functioning on a scale of 1 to 10 with a lower score indicating less of an impact of Crohn's disease on work or daily life functioning. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Score on a Scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1496, 1108, 0) | Visit 2 (n=1316, 895, 94) | Visit 3 (n=1235, 797, 143) | Visit 4 (n=1192, 738, 159) | Visit 5 (n=1128, 694, 179) | Visit 6 (n=1077, 638, 201) | Visit 7 (n=1030, 601, 207) | Visit 8 (n=1025, 571, 221) | Visit 9 (n=982, 542, 222) | Visit 10 (n=934, 514, 225) | Visit 11 (n=925, 521, 235) | |
| Remicade | 5.9 | 4.2 | 3.8 | 3.6 | 3.4 | 3.3 | 3.2 | 3.3 | 3.3 | 3.1 | 3.2 |
| Standard Therapy | 4.9 | 3.7 | 3.2 | 2.9 | 3.0 | 2.7 | 2.8 | 2.7 | 2.6 | 2.4 | 2.4 |
| Switched to Remicade | NA | 5.5 | 4.8 | 4.3 | 4.0 | 3.9 | 3.6 | 3.5 | 3.5 | 3.6 | 3.6 |
Alive in continuous complete remission with functioning original allograft. The Event Free Survival (EFS) will be estimated by the Kaplan-Meier method. (NCT00066469)
Timeframe: 2 years
| Intervention | percentage of participants analyzed (Number) |
|---|---|
| Cyclophosphamide, Prednisone, Rituximab | 71 |
9 reviews available for prednisone and Duncan Disease
| Article | Year |
|---|---|
Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.
Topics: Alleles; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Calcine | 2021 |
Belatacept for kidney transplant recipients.
Topics: Abatacept; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antilymphocyte Se | 2014 |
Post-transplant lymphoproliferative disorder presenting as multiple myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2010 |
Myasthenia gravis, an autoimmune manifestation of lymphoma and lymphoproliferative disorders: case reports and review of literature.
Topics: 2-Chloroadenosine; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2012 |
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2003 |
Progressive thrombosis after treatment of diffuse large cell non-Hodgkin's lymphoma and concomitant lupus anticoagulant.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiphospholipid Syndrome; Cyclophosphamide; | 1996 |
Low-dose chemotherapy for children with post-transplant lymphoproliferative disease.
Topics: Child; Child, Preschool; Cyclophosphamide; Drug Therapy, Combination; Graft Survival; Humans; Immuno | 2002 |
Radiation therapy in lymphomatoid granulomatosis.
Topics: Cyclophosphamide; Female; Granuloma; Granulomatosis with Polyangiitis; Humans; Lymphoma; Lymphoproli | 1978 |
Lymphoproliferative disorders after renal transplantation in patients receiving triple or quadruple immunosuppression.
Topics: Actuarial Analysis; Antilymphocyte Serum; Azathioprine; Carcinoma; Cyclosporine; Graft Survival; Her | 1992 |
7 trials available for prednisone and Duncan Disease
| Article | Year |
|---|---|
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B-Lympho | 2017 |
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B-Lympho | 2017 |
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B-Lympho | 2017 |
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B-Lympho | 2017 |
Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report.
Topics: Adolescent; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Confidence Inte | 2005 |
Two-year experience with FK 506 in pediatric patients.
Topics: Adolescent; Azathioprine; Child; Child, Preschool; Cyclosporine; Follow-Up Studies; Graft Survival; | 1993 |
[Anxiety and depression during chemotherapy for lymphoproliferative diseases].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Cyclophosphamide; | 1996 |
Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cinchona Alkaloids; Cyclophosphamide; D | 2000 |
A randomized prospective comparison of chemotherapy to total body irradiation as initial treatment for the indolent lymphoproliferative diseases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Clinic | 1987 |
89 other studies available for prednisone and Duncan Disease
| Article | Year |
|---|---|
Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD).
Topics: Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cyclophosphamide; Doxorubicin; | 2021 |
Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 2023 |
Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 2023 |
Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 2023 |
Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 2023 |
Application of contrast-enhanced ultrasonography in the diagnosis of post-kidney transplant lymphoproliferative disorder in native kidney- a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Contrast Media; Cyclophosphamide; Doxorubicin; | 2019 |
Methotrexate-associated lymphoproliferative disorder demonstrating composite lymphoma of EBV-negative diffuse large B-cell lymphoma and EBV-positive mucocutaneous ulcer.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Composite Lymphoma; Cyclophospham | 2020 |
Successful treatment of EBV-related lymphoproliferative disease after heart transplantation with autologous hematopoietic stem cell transplantation despite transient heart failure associated with engraftment syndrome.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epstein-B | 2021 |
First case of classical Hodgkin-like EBV-positive lymphoproliferative disorder under ruxolitinib therapy.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Deoxycytidine; DNA, Viral | 2021 |
Real-world Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ Transplant.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Com | 2020 |
Outcomes of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Agents | 2021 |
Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Doxorubicin; Etoposide; Hum | 2021 |
DA-EPOCH-R for post-transplant lymphoproliferative disorders.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposid | 2017 |
Iatrogenic immunodeficiency-associated Epstein-Barr virus (EBV) -negative natural killer cell lymphoproliferative disorder in a patient undergoing rheumatoid arthritis therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Cyclophosphamide; Doxor | 2017 |
Orbital T-cell lymphoma versus lupus panniculitits: a T-cell-mediated spectrum of orbital lymphoproliferative disease.
Topics: Administration, Oral; Adult; Diagnosis, Differential; Glucocorticoids; Humans; Immunosuppressive Age | 2018 |
Extreme hypercalcemia in a kidney transplant recipient.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2018 |
Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Child; Child, Prescho | 2019 |
Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epstein-Barr Vi | 2019 |
Methotrexate-associated lymphoproliferative disorder in the stomach and duodenum: a case report.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antirh | 2019 |
Remission of Late-Onset Post-Liver Transplantation Non-Hodgkin Lymphoma.
Topics: Adult; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cycloph | 2019 |
Chemoimmunotherapy and withdrawal of immunosuppression for monomorphic posttransplant lymphoproliferative disorders.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
EBV and posttransplantation lymphoproliferative disease: what to do?
Topics: Adult; Allografts; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2013 |
Methotrexate-associated lymphoproliferative disorder arising in the retromolar triangle and lung of a patient with rheumatoid arthritis.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antirh | 2014 |
Successful treatment of Rituximab-resistant Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using R-CHOP.
Topics: Adult; Anemia, Aplastic; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2014 |
Steroid-responsive atypical marginal zone hyperplasia of the lip in a child.
Topics: Antibodies, Bacterial; Biomarkers; Biopsy; Child; Diagnosis, Differential; Female; Helicobacter pylo | 2015 |
Primary Central Nervous System Immunomodulatory Therapy-Induced Lymphoproliferative Disorder in a Patient with Ulcerative Colitis: A Case Report and Review of the Literature.
Topics: Anti-Inflammatory Agents; Azathioprine; Colitis, Ulcerative; Female; Humans; Immunologic Deficiency | 2015 |
Post-Transplant Lymphoproliferative Disorder (PTLD) Manifesting in the Oral Cavity of a 13-Year-Old Liver Transplant Recipient (LTx).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biliary Atresia; Cyclophosphamide; Doxor | 2015 |
Gastric Mucosa-associated Lymphoid Tissue Lymphoma: Posttransplant Lymphopoliferative Disorder.
Topics: Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; H | 2016 |
Soft Palate Ulcer: An Unusual Presentation of a Posttransplant Lymphoproliferative Disorder.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Carcinoma, Papillary; Cyc | 2017 |
Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azathio | 2017 |
Low viral load post-transplant lymphoproliferative disease localized within the tongue.
Topics: Abscess; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cecum; Child; Epstein-Barr | 2008 |
Extradural thoracic spinal cord compression: unusual initial presentation of post-transplant lymphoproliferative disorder.
Topics: Adult; alpha 1-Antitrypsin Deficiency; Antineoplastic Combined Chemotherapy Protocols; Cyclophospham | 2008 |
Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2008 |
T-cell lymphoproliferative disorder following mycophenolate treatment for myasthenia gravis.
Topics: Aged; Biomarkers; Epstein-Barr Virus Infections; Female; Genitalia, Female; Gingiva; Gingivitis; Hum | 2009 |
Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2009 |
Idiopathic pulmonary lymphoid diffuse hyperplasia.
Topics: Aged; Female; Glucocorticoids; Humans; Hyperplasia; Lung; Lung Diseases; Lymphoproliferative Disorde | 2009 |
Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sézary syndrome.
Topics: Aged; Azathioprine; B-Lymphocytes; Epstein-Barr Virus Infections; Humans; Immunocompromised Host; Im | 2011 |
Multiple clinical presentations of lymphoproliferative disorders in pediatric liver transplant recipients: a single-center experience.
Topics: Biliary Atresia; Child; Child, Preschool; Colonic Neoplasms; Cyclosporine; Drug Therapy, Combination | 2010 |
IgG4-positive dacryoadenitis and Küttner submandibular sclerosing inflammatory tumor.
Topics: Aged; Dacryocystitis; Female; Glucocorticoids; Humans; Immunoglobulin G; Lacrimal Apparatus; Lymphop | 2010 |
Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Diagnosis, Diff | 2010 |
Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Muri | 2011 |
Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2011 |
Multifocal cranial plasmablastic lymphoma as a rare manifestation of posttransplant lymphoproliferative disorder.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Facial | 2012 |
EBV-associated lymphoproliferative disorders misdiagnosed as Crohn's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Diseases; Crohn Disease; Cyclopho | 2013 |
Acute lymphoblastic leukemia in the context of a disorder resembling X-linked lymphoproliferative (XLP) syndrome.
Topics: Adolescent; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infec | 2002 |
Long-term survival after post-transplant lymphoproliferative disease in children.
Topics: Adolescent; Azathioprine; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Immunosuppress | 2002 |
KSHV- and EBV-associated germinotropic lymphoproliferative disorder.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Clone Cells; Cyclophosphamide; Doxorubicin; | 2002 |
Tailored chemotherapy for malignant lymphoma arising in the setting of posttransplant lymphoproliferative disorder after solid organ transplantation.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Burkitt Lymphoma; Chemotherap | 2002 |
Posttransplantation lymphoproliferative disorder presenting as a unilateral leg mass 10 years after kidney transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epstein-Barr Vi | 2002 |
Fatal EBV-related post-transplant lymphoproliferative disorder (LPD) after matched related donor nonmyeloablative peripheral blood progenitor cell transplant.
Topics: Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxor | 2003 |
Therapeutic trials for a rabbit model of EBV-associated Hemophagocytic Syndrome (HPS): effects of vidarabine or CHOP, and development of Herpesvirus papio (HVP)-negative lymphomas surrounded by HVP-infected lymphoproliferative disease.
Topics: Animals; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cell L | 2003 |
Large doses of prednisone and prednisolone in the treatment of malignant lymphoproliferative disorders.
Topics: Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders | 1962 |
A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Co | 2003 |
An aggressive extranodal NK-cell lymphoma arising from indolent NK-cell lymphoproliferative disorder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorub | 2005 |
Treatment of PTLD with rituximab or chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; | 2006 |
EBV B lymphoma cell lines from patients with post-transplant lymphoproliferative disease are resistant to TRAIL-induced apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, | 2006 |
Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Bleomycin; | 2006 |
CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Disea | 2007 |
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antine | 2008 |
Amyloidosis: a changing clinical perspective.
Topics: Adult; Aged; Amyloidosis; Antibodies, Monoclonal; Bone Marrow; Bone Marrow Transplantation; Colchici | 2007 |
Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2007 |
Conjunctival posttransplantation lymphoproliferative disorder.
Topics: Biomarkers; Bone Marrow Transplantation; Child; Conjunctival Diseases; Cyclosporine; DNA, Viral; Eps | 2007 |
Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2007 |
Posttransplant Epstein-Barr virus related lymphoproliferative disorder with a primary cutaneous presentation.
Topics: Dose-Response Relationship, Drug; Epstein-Barr Virus Infections; Face; Humans; Immunosuppression The | 2007 |
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy.
Topics: Adolescent; Adult; Cadaver; Cyclosporins; Female; Heart Transplantation; Herpesviridae Infections; H | 1984 |
Treatment of refractory lymphoproliferative diseases with daily, low-dose vincristine, continuous infusion of bleomycin, and high-dose prednisone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cell Count; Female; Ho | 1984 |
Radial segmentation of nuclei (Rieder cells): a morphological marker of T-cell neoplasms?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Nucleus; Cell Transformation, Neoplastic | 1983 |
Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK 506.
Topics: Adolescent; Adult; Antihypertensive Agents; Azathioprine; Cardiac Catheterization; Child; Cyclospori | 1995 |
Aggressive treatment for postcardiac transplant lymphoproliferation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine | 1995 |
The appearance of Kaposi sarcoma during corticosteroid therapy.
Topics: Adult; Aged; Autoimmune Diseases; Azathioprine; Betamethasone; Female; Humans; Lymphoproliferative D | 1993 |
Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children.
Topics: Adolescent; Age Factors; Antiviral Agents; Azathioprine; Child; Child, Preschool; Cyclosporine; Foll | 1997 |
Long-term allograft acceptance in a patient with posttransplant lymphoproliferative disorder: correlation with intragraft viral interleukin-10.
Topics: Adult; DNA, Viral; Down-Regulation; Female; Graft Survival; Herpesvirus 4, Human; Humans; Immunosupp | 1997 |
The clinical diversity and role of chemotherapy in lymphoproliferative disorder in liver transplant recipients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Herpes | 1997 |
Treatment of post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation with low-dose chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cyclophosphamide; Dise | 1998 |
Clinical outcomes associated with conversion to tacrolimus-based immunosuppression in pediatric cardiac transplantation.
Topics: Adolescent; Azathioprine; Child; Child, Preschool; Cyclosporine; Drug Therapy, Combination; Female; | 1998 |
One hundred children treated with tacrolimus after primary orthotopic liver transplantation.
Topics: Child; Child, Preschool; Drug Administration Schedule; Follow-Up Studies; Graft Rejection; Graft Sur | 1998 |
Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Cohort Studies; Epstein-Barr Virus Infections | 1998 |
Cyclosphosphamide/prednisone for combination immunosuppression and therapy of lymphoproliferative disease.
Topics: Cyclophosphamide; Drug Therapy, Combination; Follow-Up Studies; Glucocorticoids; Heart Transplantati | 1999 |
Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineopl | 2000 |
Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome.
Topics: Apoptosis; Autistic Disorder; Autoimmune Diseases; Child, Preschool; DNA Mutational Analysis; fas Re | 2000 |
Use of radiation therapy in posttransplant lymphoproliferative disorder (PTLD) after liver transplantation.
Topics: Algorithms; Cyclosporine; Epstein-Barr Virus Infections; Female; Graft Rejection; Hepatitis C; Human | 2000 |
Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center.
Topics: Adult; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubi | 2000 |
Lymphoproliferative disease of granular T lymphocytes presenting as aplastic anemia.
Topics: Adult; Aged; Anemia, Aplastic; Bone Marrow Cells; Cyclophosphamide; Cytogenetic Analysis; Diagnosis, | 2000 |
[Fainting after drinking a glass of whiskey-soda...].
Topics: Abdominal Pain; Alcoholic Beverages; Anti-Inflammatory Agents; Ethanol; Follow-Up Studies; Hospitali | 2001 |
Non-Hodgkin's lymphoma of the ocular adnexa.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2001 |
Benign lymphoproliferation syndrome, autoimmune neutropenia and thrombocytopenia in partial Di George syndrome: efficacy of rh G-CSF and prednisone.
Topics: Autoimmune Diseases; Chronic Disease; Female; Glucocorticoids; Granulocyte Colony-Stimulating Factor | 2001 |
Modified cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone therapy for posttransplantation lymphoproliferative disease in pediatric patients undergoing solid organ transplantation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cyclophosphamide; Doxo | 2001 |
Epstein-Barr virus-negative precursor B cell lymphoblastic lymphoma after liver transplantation: a unique form of posttransplant lymphoproliferative disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; D | 2002 |
Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder.
Topics: Adolescent; Adult; Antilymphocyte Serum; Azathioprine; Cyclosporine; DNA, Viral; Female; Follow-Up S | 1992 |
Rapid transient reversal of anemia and long-term effects of maintenance intravenous immunoglobulin for autoimmune hemolytic anemia in patients with lymphoproliferative disorders.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Autoantibodies; Combined Modality The | 1988 |
Significance of multiple types of antibodies on red blood cells of patients with positive direct antiglobulin test: a study of monospecific antiglobulin reactions in 85 patients.
Topics: Antibodies, Anti-Idiotypic; Antibody Specificity; Blood Group Antigens; Coombs Test; Humans; Leukemi | 1985 |
Combined heart-lung transplantation for terminal pulmonary lymphangioleiomyomatosis.
Topics: Adult; Azathioprine; Bronchial Diseases; Cyclosporins; Female; Heart Transplantation; Heart-Lung Tra | 1985 |